[ad_1]
AUSTIN, Texas–(BUSINESS WIRE)–Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) (“Anebulo”), today announced the appointment of Bimal Shah to its Board of Directors. Mr. Shah will serve as a member of the board’s audit and compensation committees. “I am pleased to welcome Bimal to the Anebulo Board,” said Dr. Joseph Lawler, Anebulo’s Chairman. “Bimal’s depth of fina
[ad_2]
Source link